Moderna to Develop Mrna-Based Shingles Vaccine

Reuters2022-02-18

Feb 18 (Reuters) - Moderna Inc said on Friday it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles.

The success of COVID-19 vaccines based on messenger RNA (mRNA) technology from Moderna and rival Pfizer has prompted efforts to use the novel technology in other vaccines and therapeutics targeted at hard-to-treat diseases.

Pfizer is also developing an mRNA-based vaccine for shingles and expects to begin clinical trials in the second half of 2022.

If successful, both companies will compete with GlaxoSmithKline's two-dose vaccine Shingrix, which was approved by the U.S. Food and Drug Administration in 2017.

Shingles typically develops in older adults who were infected with chicken pox, or the varicella-zoster virus, when younger. It is characterized by a painful rash that generally clears up within a month.

Moderna's shingles vaccine is being developed to target the varicella-zoster virus.

The company is also developing a cancer vaccine and a shot against the herpes simplex virus-2, which causes genital herpes, a sexually transmitted disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

vaicrazy
2022-02-19
vaicrazy
Good
RS142
2022-02-19
RS142
Pipeline of products..good
SteadyDoesIt
2022-02-18
SteadyDoesIt
Sounds promising
Anzygart
2022-02-18
Anzygart
Cool
aaronh
2022-02-18
aaronh
Great
BBBBBBBBBB
2022-02-18
BBBBBBBBBB
K

Leave a comment

7

49

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2212162467?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-18 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2212162467","market":"us","top_or_hot":-1,"title":"Moderna to Develop Mrna-Based Shingles Vaccine","media":"Reuters","content":"<html><head></head><body><p>Feb 18 (Reuters) - Moderna Inc    said on Friday it is developing three new vaccines based on the same technology used for its COVID-19 shot, including <a href=\"https://laohu8.com/S/AONE.U\">one</a> for viral infection shingles.</p><p>The success of COVID-19 vaccines based on messenger RNA (mRNA) technology from Moderna and rival Pfizer    has prompted efforts to use the novel technology in other vaccines and therapeutics targeted at hard-to-treat diseases.</p><p>Pfizer is also developing an mRNA-based vaccine for shingles and expects to begin clinical trials in the second half of 2022.</p><p>If successful, both companies will compete with GlaxoSmithKline&#39;s    two-dose vaccine Shingrix, which was approved by the U.S. Food and Drug Administration in 2017.</p><p>Shingles typically develops in older adults who were infected with chicken pox, or the varicella-zoster virus, when younger. It is characterized by a painful rash that generally clears up within a month.</p><p>Moderna&#39;s shingles vaccine is being developed to target the varicella-zoster virus.</p><p>The company is also developing a cancer vaccine and a shot against the herpes simplex virus-2, which causes genital herpes, a sexually transmitted disease.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna to Develop Mrna-Based Shingles Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna to Develop Mrna-Based Shingles Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n2022-02-18 21:47 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 18 (Reuters) - Moderna Inc    said on Friday it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles.The success of ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"2212162467","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2212162467","pubTimestamp":1645192069,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 18 (Reuters) - Moderna Inc    said on Friday it is developing three new vaccines based on the sa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","PFE":"辉瑞","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓","MRNA":"Moderna, Inc.","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Moderna将开发基于mRNA的带状疱疹疫苗","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"PFE":0.9,"BNTX":0.61},"content_text":"Feb 18 (Reuters) - Moderna Inc    said on Friday it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles.The success of COVID-19 vaccines based on messenger RNA (mRNA) technology from Moderna and rival Pfizer    has prompted efforts to use the novel technology in other vaccines and therapeutics targeted at hard-to-treat diseases.Pfizer is also developing an mRNA-based vaccine for shingles and expects to begin clinical trials in the second half of 2022.If successful, both companies will compete with GlaxoSmithKline's    two-dose vaccine Shingrix, which was approved by the U.S. Food and Drug Administration in 2017.Shingles typically develops in older adults who were infected with chicken pox, or the varicella-zoster virus, when younger. It is characterized by a painful rash that generally clears up within a month.Moderna's shingles vaccine is being developed to target the varicella-zoster virus.The company is also developing a cancer vaccine and a shot against the herpes simplex virus-2, which causes genital herpes, a sexually transmitted disease.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9094444401,"gmtCreate":1645229765387,"gmtModify":1676534010363,"author":{"id":"3573989963279471","authorId":"3573989963279471","name":"vaicrazy","avatar":"https://static.tigerbbs.com/5e1fe01bd5dda3f3a00e7197697a8873","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3573989963279471","authorIdStr":"3573989963279471"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094444401","repostId":2212162467,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094466361,"gmtCreate":1645224115101,"gmtModify":1676534009500,"author":{"id":"3574118564601995","authorId":"3574118564601995","name":"RS142","avatar":"https://static.tigerbbs.com/22d2d9b1f352da24e6ea75b557ac987a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574118564601995","authorIdStr":"3574118564601995"},"htmlText":"Pipeline of products..good","listText":"Pipeline of products..good","text":"Pipeline of products..good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094466361","repostId":2212162467,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094402498,"gmtCreate":1645197590215,"gmtModify":1676534008268,"author":{"id":"4087620073091560","authorId":"4087620073091560","name":"SteadyDoesIt","avatar":"https://static.tigerbbs.com/ab599edb0711e3b18e0dda8931ea8e4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087620073091560","authorIdStr":"4087620073091560"},"htmlText":"Sounds promising","listText":"Sounds promising","text":"Sounds promising","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094402498","repostId":2212162467,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094400339,"gmtCreate":1645196624935,"gmtModify":1676534008110,"author":{"id":"4087708380401170","authorId":"4087708380401170","name":"Anzygart","avatar":"https://static.tigerbbs.com/5255e6a87df642eff53b65456895ac13","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087708380401170","authorIdStr":"4087708380401170"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094400339","repostId":2212162467,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094579607,"gmtCreate":1645195273796,"gmtModify":1676534007807,"author":{"id":"3572385806607275","authorId":"3572385806607275","name":"aaronh","avatar":"https://static.tigerbbs.com/4633f061d6a91b98037c28e4007151ac","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3572385806607275","authorIdStr":"3572385806607275"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094579607","repostId":2212162467,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094543360,"gmtCreate":1645193783298,"gmtModify":1676534007608,"author":{"id":"3581562365927542","authorId":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581562365927542","authorIdStr":"3581562365927542"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094543360","repostId":2212162467,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":49,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2212162467"}